Add Formweb to your mobile device
Following is a P and T Committee update (from the August 23rd meeting). Starting date for specific programs is 6 Sept 2016, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red.
Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.
|
Drug or Drug Class |
Formulary Decision |
Comments |
| emtricitabine-tenofovir alafenamide (Descovy) | Formulary (Not Routinely Stocked) |
Inpatients are encouraged to utilize their own supply if available. Descovy will be dispensed as separate agents when tenofovir alafenamide becomes commercially available as a separate agent. |
| emtricitabine/rilpivirine/ tenofivir alafenamide (Odefsey) | Formulary (Not Routinely Stocked) |
Inpatients are encouraged to utilize their own supply if available. Odefsey will be dispensed as separate agents when tenofovir alafenamide becomes commercially available as a separate agent. |
| Emtricitabine/elvitegravir /cobicistat/tenofivir alafenamide (Genvoya) | Reclassified as Formulary (Not Routinely Stocked) |
Inpatients are encouraged to utilize their own supply if available. Genvoya will be dispensed as separate agents when tenofovir alafenamide becomes commercially available as a separate agent. |
| cefepime shortage | Automatic Interchange Approved |
Cefepime is on national backorder. To conserve current stock, an automatic interchange program went into effect August 10th, 2016. Interchanges to alternative antibiotic regimens will continue until cefepime is available. |
| olaparib (Lynparza) | Non-Formulary | Inpatients may use home supply. |
| linagliptin/metformin XR (Jentadueto XR) | Non-Formulary | Each individual component will be dispensed separately. |
| ixekizumab (Taltz) | Non-Formulary | Inpatients may use home supply. |
| dichlorphenamide (Keveyis) | Non-Formulary | Inpatients may use home supply. |
| Nuclear Medicine Update | 47 Agents – Formulary |
Review of all FDA-approved radiopharmaceuticals available through CardinalHealth. Not all agents will be stocked, but may be procured as needed. |
| minocycline 75 mg | Reclassified as Non-Formulary Dosage Interchange Approved | Low use resulting in wasted product. Orders for 75 mg will be converted to 100 mg. |
| erythromycin (Erytab) 333 mg | Reclassified as Non-Formulary Dosage Interchange Approved |
Low use resulting in wasted product. Orders for 333 mg every 8 hours will be converted to 250 mg every 6 hours. |
| diflunisal (Dolobid) | Reclassified as Non-Formulary Therapeutic Interchange Approved |
Low use resulting in wasted product. Orders for diflunisal will be converted to ibuprofen at an equivalent regimen. |
| bisoprolol-hydrochlorothiazide (Ziac) | Reclassified as Non-Formulary Dosage Interchange Approved |
Each individual component will be dispensed separately. Bisoprolol converts to metoprolol succinate following current interchange programs and hydrochlorothiazide 6.25 mg will be converted to 12.5 mg (lowest available dosage). |
| Sepsis Protocol – Update | Protocol Revisions Approved | The committee approved updates to weight-based fluid resuscitation with normal saline and antibiotic options that better align with core measures. The protocol requires further review by other institutional committees. |
| Fecal Microbiota Transplant (FMT) Policy | Policy Approved | Policy details proper ordering, receipt, storage, preparation, administration, disposal, and monitoring of OpenBiome formulations with different routes of administration (oral, nasogastric tube, or colonoscopy). |